Ryan Horne

Ryan Horne

Auto-generated profile, based on publicly available information

Ryan Horne

University of Iowa Carver College of Medicine Iowa City lowa USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 May 2023 in Acta Biomaterialia
Verified
Journal Article
Closed access
RHRyan Horne
Ryan Horne
NBNir Ben-Shlomo
Nir Ben-Shlomo
MJMegan Jensen
Megan Jensen
MEMorgan Ellerman
Morgan Ellerman
CECaleb Escudero
Caleb Escudero
MHMarlan R. Hansen
Marlan R. Hansen

1 October 2017 in Journal of Drug Delivery Science and Technology
Verified
Journal Article
Closed access
RHRyan R. Horne
Ryan R. Horne
KJKevin E. Judd
Kevin E. Judd
WPWilliam G. Pitt
William G. Pitt

29 November 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
RHRyan Horne
Ryan Horne
NBNir Ben-Shlomo
Nir Ben-Shlomo
MJMegan Jensen
Megan Jensen
MEMorgan Ellerman
Morgan Ellerman
CECaleb Escudero
Caleb Escudero
MHMarlan R. Hansen
Marlan R. Hansen
The foreign body response to implanted materials often complicates the functionality of sensitive biomedical devices. For cochlear implants, this response can reduce device performance, battery life and preservation of residual acoustic hearing. As a permanent and passive solution to the foreign body response, this work investigates ultra-low-fouling poly(carboxybetaine methacrylate) (pCBMA) thin film hydrogels that are simultaneously photo-grafted and photo-polymerized onto polydimethylsiloxane (PDMS). The cellular anti-fouling properties of these coatings are robustly maintained even after six-months subcutaneous incubation and over a broad range of cross-linker compositions. On pCBMA-coated PDMS sheets implanted subcutaneously, capsule thickness and inflammation are reduced significantly in comparison to uncoated PDMS or coatings of polymerized poly(ethylene glycol dimethacrylate) (pPEGDMA) or poly(hydroxyethyl methacrylate) (pHEMA). Further, capsule thickness is reduced over a wide range of pCBMA cross-linker compositions. On cochlear implant electrode arrays implanted subcutaneously for one year, the coating bridges over the exposed platinum electrodes and dramatically reduces the capsule thickness over the entire implant. Coated cochlear implant electrode arrays could therefore lead to persistent improved performance and reduced risk of residual hearing loss. More generally, the in vivo anti-fibrotic properties of pCBMA coatings also demonstrate potential to mitigate the fibrotic response on a variety of sensing/stimulating implants. Graphical

7 March 2025 in Laryngoscope Investigative Otolaryngology
Verified
Journal Article
Open access
RHRyan Horne
Ryan Horne
CECaleb Escudero
Caleb Escudero
MEMorgan Ellerman
Morgan Ellerman
CGC. Allan Guymon
C. Allan Guymon
MHMarlan Hansen
Marlan Hansen
Objective: To determine the effects of zwitterionic hydrogel films on mucus contact angles, flow, and stasis with respect to medical polymer surfaces, both flat and tubular.Methods: A zwitterionic hydrogel thin film was photografted onto medical rubber surfaces and compared against non‐zwitterionic hydrogel thin films and untreated surfaces to determine its impact on mucus contact angles, mucus flow on sheets and tubes, and mucus plugging.Results: Zwitterionic and conventional hydrogel films significantly reduce the mucus contact angles and the tilt required to initiate mucus flow on sheets and in tubular systems. Preliminary experiments show that these films may also shorten the time required for a mucus‐plugged tube to unplug when exposed to saline.Conclusion: Zwitterionic and conventional hydrogel films on typical medical surfaces reduce resistance to mucus flow, increase mucus discharge, and may facilitate faster unplugging of dried mucus. These effects are the most pronounced on tubes of larger inner diameter (greater than 2.6 mm) and tend to dissipate for tubes of smaller diameter. These results may help guide future improvements to medical tubes intended to discharge mucus and ventilate, resulting in fewer complications for patients.Level of Evidence: Level 2, randomized individual trial.